Maintaining an impact factor of 3.0 highlights the sustained value of the research published in Haemophilia and demonstrates its ongoing contribution to the scientific community. As the official journal of both the World Federation of Hemophilia (WFH) and the European Association for Haemophilia and Allied Disorders (EAHAD), the journal plays a key role in supporting the global exchange of scientific knowledge and best practices. Through original research, reviews, guidelines, and educational content, the journal helps advance evidence-based care and foster international collaboration.
This achievement reflects the dedication of our authors, the expertise and commitment of the peer reviewers who help ensure scientific rigor, and the impact of our journal on the global inherited bleeding disorders community.
—Cedric Hermans, MD, PhD, Editor, Haemophilia, and Vice President, Medical, WFH
As one of the leading scientific journals dedicated exclusively to bleeding disorders and comprehensive care, Haemophilia continues to serve as a trusted source of knowledge for clinicians, researchers, allied healthcare professionals, and patient advocates around the world. The journal provides a platform for the latest advances in diagnosis, treatment, patient outcomes, and emerging therapies, helping to inform clinical practice and improve care for people living with inherited bleeding disorders.
The WFH extends its appreciation to Cedric Hermans, MD, PhD, the journal’s Editor-in-Chief and Vice President, Medical, WFH; and the associate editors; reviewers, authors, and readers whose commitment makes the journal’s continued success possible.
Looking ahead, Haemophilia remains committed to publishing high-quality research that advances evidence-based care and improves outcomes for people living with bleeding disorders worldwide.
To find out more about Haemophilia, please click here.










